<DOC>
	<DOCNO>NCT00123851</DOCNO>
	<brief_summary>This trial design investigate safety , tolerability effectiveness OSI-774 ( tarceva ) combine oxaliplatin capecitabine treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Tarceva , Capecitabine Oxaliplatin Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Patients treat OSI-774 ( orally ) daily , oxaliplatin ( intravenously ) every 3 week , capecitabine ( orally ) twice daily 14 day follow 7-day rest period . This constitute 21-day treatment cycle . Treatment continue disease progression unacceptable toxicity occur .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Ability understand willingness sign write informed consent document . Patients histologic proof adenocarcinoma colon rectum ( colorectal carcinoma ) evidence metastatic disease . Patients must receive one ( 1 ) prior chemotherapy regimen metastatic disease . Patients receive adjuvant therapy 1 regimen metastatic disease eligible . Patients receive adjuvant therapy recur within 12 month completion adjuvant therapy also eligible . Patients receive prior radiation therapy , either adjuvant metastatic setting , colorectal carcinoma . All following must apply : Greater 4 week must elapse time major surgery patient must recover effect ( e.g. , laparotomy ) ; *Greater 2 week must elapse time minor surgery patient must recover operation . ( Insertion vascular access device consider major minor surgery . ) ; Greater 4 week must elapse time major radiotherapy [ RT ] ( e.g. , chest bone palliative RT ) ; Greater 4 week must elapse completion previous chemotherapy patient must recover related toxicity ; Greater 4 week must elapse participation investigational drug study . ECOG performance status &lt; 2 ; life expectancy &gt; 12 week Patients must normal organ marrow function define : ANC &gt; 1500/mm3 ; hemoglobin &gt; 9.0 gm/dl ; platelet &gt; 100,000/mm3 ; SGOT &lt; 2.5x upper limit normal evidence liver metastases &lt; 5x upper limit normal evidence liver metastasis ; total bilirubin &lt; 1.5x upper limit normal ; Alk Phos &lt; 2.5x upper limit normal ( &lt; 5x upper limit normal evidence liver metastases &lt; 10x upper limit normal evidence bone disease ) . Patients peripheral neuropathy grade 2 great severity . Uncontrolled high blood pressure . Unstable angina . Symptomatic congestive heart failure . Myocardial infarction &lt; 12 month prior registration . Serious uncontrolled cardiac arrhythmia . New York Heart Association classification III IV . Active uncontrolled infection . Medical psychiatric condition , opinion investigator , make participation investigational trial nature poor risk . Patients know brain metastasis carcinomatous meningitis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . No concurrent malignancy site , except limited basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix . Patients childbearing potential must negative serum pregnancy test within 7 day prior registration agree use effective method contraception . Patients pregnant lactate . Patients prior unanticipated severe reaction fluoropyrimidine therapy , know sensitivity 5fluorouracil . Patients previously treat oxaliplatin , OSI774 another epidermal growth factor inhibitor ( EGFR ) . Patients lack physical integrity upper gastrointestinal tract . Patients serious uncontrolled medical condition investigator feel might compromise study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Colorectal</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>